Should Investors Exit From This NASDAQ-Listed Pharmaceutical Stock – ACRX

AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company that develops and commercializes medications in medically supervised settings. Two of the company's medicines for moderate-to-severe acute pain are DSUVIA and Zalviso. ARX-02 and ARX-03 are two forthcoming products from the firm.

Why should Investors make an Exit?

• Fall-in topline and continuous losses: ACRX witnessed a significant decline in total revenue to USD 2.82 million in FY21 (ended December 31, 2021) from USD 5.42 million in FY20. It is a loss-making entity and incurred a loss of USD 35.10 million in FY21 and USD 40.38 million in FY20 due to higher operating costs, resulting in negative profit margins.
• Macro Headwinds: Unless organic cash from normal business operations is robust, recent market discussions about raising interest rates sooner to combat inflation will pressure the corporation to increase short-term borrowing for working capital. This is a temporary stumbling hurdle that makes it less appealing to investors.
• Bearish Technical Indicator: On the daily chart, ACRX prices are sustaining below the downward sloping trend line and facing the resistance of the same. Furthermore, the momentum oscillator RSI (14-period) is trading at ~34.21. On the weekly chart, the prices are trading below the trend-following indicators 21-period and 50-period SMA, which may act as a resistance level for the stock.

Valuation Methodology: Price/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

ACRX's share price has remained on a bearish trend, fallen 82.41% in the past twelve months and is currently leaning close to the lower end of its 52-week range of USD 0.27 to USD 1.72. We have valued the stock using the Price/ Sales multiple based on relative valuation methodology and arrived at a target price of USD 0.23.

Based on the continuous losses, decline in topline, macro headwinds, current valuation, and bearish technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 0.2832, up 1.36%, as of March 30, 2022.

Three-Year Technical Price Chart (as of March 30, 2022). Source: REFINITIV, Analysis by Kalkine Group

*All forecasted figures and Industry Information have been taken from REFINITIV.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.